BioCentury | Jul 31, 2020
Distillery Therapeutics

Targeting the metabolic enzyme DGAT1 to treat glioblastoma

...I testing for metabolic disorders. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Viking Therapeutics Inc. (NASDAQ:VKTX) have DGAT1 inhibitors...
BioCentury | Nov 27, 2019
Product Development

Early Pfizer data from DGAT2-targeting NASH program lay groundwork for monotherapy and combos

Pfizer thinks Phase I and preclinical data from its DGAT2 program suggest the target could hit NASH's three mechanistic pillars -- dysregulated metabolism, inflammation and fibrosis. The pharma is advancing a next-generation compound both alone...
BioCentury | Feb 20, 2019
Distillery Therapeutics

Autoimmune disease

...the CNS and demyelination in the spinal cord. Next steps include testing undisclosed small molecule DGAT1 inhibitors...
...in Phase I testing for metabolic disorders. Ligand Pharmaceuticals Inc. and Viking Therapeutics Inc. have DGAT1 inhibitors...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
BioCentury | Nov 2, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
BioCentury | Oct 29, 2018
Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
BioCentury | Oct 5, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for...
BioCentury | Oct 3, 2018
Company News

Boston Pharmaceuticals licenses three Novartis antibacterials, five GSK programs

Boston Pharmaceuticals Inc. (Cambridge, Mass.) in-licensed eight products through a pair of deals with Novartis AG (NYSE:NVS; SIX:NOVN) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Boston acquired exclusive, global rights to three anti-infective compounds from Novartis for...
BioCentury | Jan 21, 2016
Distillery Therapeutics

Therapeutics: Diacylglycerol O-acyltransferase-2 (DGAT2)

Endocrine/metabolic disease INDICATION: Dyslipidemia In vitro and mouse studies identified a DGAT2 inhibitor that could help treat dyslipidemia and other metabolic disorders. Screening of a small molecule library in enzymatic assays and optimization of hits...
BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Diacylglycerol O-acyltransferase-2 (DGAT2)

Endocrine/metabolic disease INDICATION: Hypercholesterolemia In vitro and mouse studies identified a DGAT2 inhibitor that could help treat hypercholesterolemia. Chemical synthesis and testing in DGAT2 activity assays of imidazopyridine analogs identified a compound that inhibited DGAT2...
Items per page:
1 - 10 of 23